GoutHealth Care Utilization in Patients with Gout
Section snippets
Methods
This study was conducted as part of a larger study validating a new gout-specific health-related quality-of-life instrument (8). The sample was recruited from gout patients attending a variety of clinics (eg, rheumatology, primary care) in 3 U.S. cities (San Diego, Cincinnati, and Minneapolis) using physician in-office recruitment, patient response to clinic posters, and local newspaper advertisements. Inclusion criteria were as follows: age between 18 and 85, presence of gout as determined by
Results
The original cohort consisted of a total of 298 patients who completed the study questionnaire. Of the original cohort, 296 (99.3%) provided utilization data and are included in the current study (Fig. 1). Physicians responded for 224 patients, with gout diagnosis confirmed for 202 of the patients for whom physicians provided supporting data (90.2%). Sixty percent of patients were recruited from the 3 VA medical centers and 40% from private practices.
Demographic and clinical information about
Discussion
In our study, primary care physician visits were the most frequently cited health care resource for gout treatment and rheumatologist visits were the second most frequently used resource. Patients used each of these visit types an average of 3 times in the year before the survey. Slightly more than 1/3 of patients had used emergency room or urgent care facilities for their gout treatment, which is more costly than outpatient care. Our overall gout severity composite measure, physician-rated
Acknowledgments
This work was supported in part by an investigator-initiated research grant from Takeda Pharmaceutical Products, Inc, VA Research Service, and the University of California, San Diego General Clinical Research Center Program, M01 RR00827, National Center for Research Resources, National Institutes of Health.
References (29)
- et al.
The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994
Am J Kidney Dis
(2002) - et al.
A literature review of the epidemiology and treatment of acute gout
Clin Ther
(2003) - et al.
The economic burden of gout on an employed population
Curr Med Res Opin
(2006) - et al.
Disease-related and all-cause health care costs of elderly patients with gout
J Manag Care Pharm
(2008) - et al.
Gout in the elderly—a population health study
J Rheumatol
(2009) - et al.
Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilization in US veterans
Ann Rheum Dis
(2008) - et al.
The effect of serum urate on gout flares and their associated costs: an administrative claims analysis
J Clin Rheumatol
(2009) - et al.
Evaluation of an instrument assessing influence of gout on health-related quality of life
J Rheumatol
(2008) - et al.
Preliminary criteria for the classification of the acute arthritis of primary gout
Arthritis Rheum
(1977) - et al.
A mathematical technique for the analysis of linear systems
Proc IRE
(1954)
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
Arthritis Rheum
Applied multiple regression/correlation analysis for the behavioral sciences
Epidemiology of gout: is the incidence rising?
J Rheumatol
Intermittent control of hyperuricemia in the treatment of gout
J Rheumatol
Cited by (43)
Study of hospital admissions for gout in a rheumatology department between 2000 and 2010 - Retrospective analysis of 114 observations
2014, Revue du Rhumatisme (Edition Francaise)Clinical characteristics and risk factors associated with bone erosion in patients with tophi
2024, Advances in RheumatologyClinical Visit Frequencies in Rheumatology: A Systematic Literature Review
2023, Arthritis Care and ResearchChange in Utilization of Health Services and its Affecting Factors in Kayseri City Center: A Comparative Population-Based Cross-Sectional Study in 2004 and 2017
2023, Turkiye Klinikleri Journal of Medical Sciences
This work was supported by the Takeda Pharmaceutical Products, Inc, VA Research Service and the University of California, San Diego General Clinical Research Center Program,M01 RR00827, National Center for Research Resources, National Institutes of Health. D.K. was also supported by a National Institutes of Health Award (NIAMS K23 AR053858-01A1) during this period. J.A.S. was supported by a National Institutes of Health CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research). R.T. was supported by the VA Research Service.
Disclosure Statement: J.A.S. has received speaker honoraria from Abbott, research grants from Department of Veterans Affairs, National Institutes of Health, Arthritis Foundation, University of Minnesota, Cochrane centers, Minnesota Medical Foundation, research and travel grants from Allergan, Takeda, Savient, Wyeth, and Amgen and consultant fees from Savient, URL Pharmaceuticals, and Novartis. J.D.H. has received a research grant from TAP and Takeda pharmaceuticals and consultant fees from Regeneron. R.T. is a consultant for Takeda, Savient, EnzymeRx, Altus, BioCryst, Regeneron, Novartis, Pfizer, URL Pharma, and Proctor & Gamble and has received grants from the Research Service of the Department of Veterans Affairs and Takeda Pharmaceuticals. D.K. has received consultant fees and research grants from Takeda Pharmaceuticals. A.K. has received consultant fees from URL pharmaceuticals. All other authors have no conflicts of interest to disclose.
“The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.”